Mounjaro 7.5Mg Kwikpen

Mounjaro 7.5Mg Kwikpen contains Tirzepatide, a dual GIP and GLP-1 receptor agonist, used to improve blood sugar control in adults with type 2 diabetes. It also aids in chronic weight management for adults who are overweight or have obesity.

Benefits

Mounjaro 7.5Mg Kwikpen helps regulate blood sugar levels by stimulating insulin release and reducing glucose production by the liver. It also contributes to weight loss by slowing digestion and acting on brain areas that control appetite, leading to increased fullness and reduced food cravings.

Uses and Indications

• Improving blood sugar control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise.
• Chronic weight management, including weight loss and maintenance, in adults with obesity (BMI ≥ 30) or who are overweight (BMI ≥ 27) with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity.
• Treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

The Mounjaro 7.5Mg Kwikpen contains:

• Tirzepatide 7.5 mg (active ingredient).
• Excipients: Sodium chloride, sodium phosphate dibasic heptahydrate, benzyl alcohol, glycerol, phenol, and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may be added to adjust pH.

Dosage and Administration

1. Mounjaro 7.5Mg Kwikpen is administered as a once-weekly subcutaneous injection.
2. The injection can be given in the abdomen, thigh, or upper arm. Rotate the injection site each week.
3. The starting dose is typically 2.5 mg once weekly for four weeks, which may then be increased to 5 mg once weekly. Further dose adjustments, up to a maximum of 15 mg once weekly, should be made by a doctor in increments of 2.5 mg at intervals of at least four weeks.
4. Each KwikPen delivers four fixed doses. After four doses, the pen should be disposed of.

Storage and Disposal

• Store unopened Mounjaro KwikPen in a refrigerator between 2°C and 8°C. Do not freeze. Keep in the original carton to protect from light.
• Once in use, the pen can be stored unrefrigerated at temperatures below 30°C for up to 30 days, or continue to be stored in the refrigerator (2°C - 8°C).
• Dispose of used pens and needles in a puncture-resistant sharps disposal container. Do not discard in household trash unless local regulations permit.

Precautions and Safety

• Mounjaro may increase the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Do not use if you or your family have a history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Acute pancreatitis has been reported; seek immediate medical attention if you experience severe, persistent abdominal pain, with or without vomiting.
• Monitor blood sugar closely if using Mounjaro with insulin or sulfonylureas, as this may increase the risk of low blood sugar (hypoglycemia).
• Serious allergic reactions, including anaphylaxis and angioedema, have occurred. Discontinue use and seek medical help if you experience symptoms of a severe allergic reaction.
• Dehydration, potentially leading to kidney problems, can occur due to gastrointestinal side effects like nausea, vomiting, and diarrhea. Stay hydrated.
• Inform your doctor about all medical conditions, especially if you have a history of pancreatitis, diabetic retinopathy, or severe gastrointestinal disease.
• Do not share your Mounjaro KwikPen with others, even if the needle is changed, to prevent serious infections.

Side Effects and Risks

• Common side effects include nausea, diarrhea, vomiting, constipation, decreased appetite, indigestion, and abdominal pain. These are usually mild to moderate and often subside over time.
• Less common but serious side effects can include acute pancreatitis, gallbladder problems, and worsening of diabetic retinopathy.

Disclaimer

Use this medicine only under the prescription and guidance of a qualified doctor or pharmacist.